Simplified superovulation protocols in dromedary camels (Camelus dromedarius)

Evaluation of a long-acting recombinant bovine FSH for multiple ovulation and embryo transfer in dromedary camels

The present study was conducted to test a new super-agonist recombinant bovine FSH (rbFSH) to induce superovulation (SOV) in dromedary camels. In experiment I, a single IM injection of 40, 60, 80, 100, or 120 µg rbFSH was administered (4 donors per group) to determine the effective dose resulting in acceptable multiple ovulation and embryo yield. Administration of 40 µg was ineffective, while 100 and 120 µg were associated with increased numbers of developed follicles, corpora lutea, and recovered embryos compared to administration of 60 and 80 µg. In experiment II, donors were divided into treatment groups to compare rbFSH with two conventional protocols for SOV. Donors received a single dose of 2000 IU eCG in combination with 400 mg porcine follicle-stimulating hormone (pFSH; Folltropin-V®; Group 1, n = 29) or 500 µg of pFSH with 100 µg of pLH (Stimufol®; Group 2, n = 16). Group 3 (n = 19) received a single dose of 100 µg rbFSH. No difference was found in the size and number of follicles per donor. Response time, ovulation rate, and the number of corpora lutea and recovered embryos per donor were similar in all groups. The number of medium-sized and transparent embryos decreased while the number of small-sized and semi-transparent embryos increased in Group 3 (rbFSH) compared to the other two groups. The pregnancy rate of the recipients at 10 days post-ET, at two months of gestation, and the rate of early pregnancy loss (EPL) did not differ among the groups. In conclusion, a single IM administration of 100 µg rbFSH induces a successful superovulation in dromedary camels and has the advantage of reducing stress associated with multiple FSH administration of the conventional protocols.

Superovulation of dromedary camels with eCG: An effective and practical technique

This study was conducted to develop simple superovulation protocols for dromedary camels using eCG. In experiment 1, camels received either 1000, 2000, 3000, 4000, 5000 or 6000 IU eCG. In experiment 2, camels received either 400 mg FSH (Folltropin-V) twice-daily over 5 days or 3000 IU eCG. In experiment 3, camels received 3000 IU eCG either at 2, 3, 4 or 5 days after ovulation induction. Ovarian response and embryo yield were evaluated in all experiments and embryos collected from camels treated with FSH and eCG were transferred to recipients to examine pregnancy rates. The mean number of ovulations (12.6 ± 1.5 and 13.3 ± 1.2 vs 3.4 ± 0.3, 6.2 ± 0.6 and 9.3 ± 1.0, respectively) and transferable embryos (4.6 ± 1.3 and 4.8 ± 1.0 vs 1.6 ± 0.2, 2.2 ± 0.4 and 1.1 ± 0.4, respectively) with 3000 and 4000 IU eCG doses were higher compared to 1000, 2000 and 6000 IU eCG doses (P < 0.05). Doses of 5000 and 6000 IU eCG resulted in a higher number of unovulatory follicles than other doses (P < 0.05). The FSH treatment resulted in higher number of ovulatory follicles (21.8 ± 1.3 vs 14.8 ± 1.7) and ovulations (18.5 ± 1.1 vs 13.9 ± 1.4) compared to eCG (P < 0.05). However, the number of transferable embryos and pregnancy rates were similar in these treatments. The timing of eCG treatment after ovulation induction did not affect the number of ovulatory follicles and transferable embryos but eCG treatment at 5 days after ovulation induction reduced the number of ovulations (P < 0.05). In conclusion, the optimal dose of eCG to induce superovulation is 3000-4000 IU and it produces a comparable embryo yield to FSH, and can be administered at 2-4 days after ovulation induction.